We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.59B
AUM Growth
+$1.11B
Cap. Flow
-$1.32B
Cap. Flow %
-13.72%
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$117M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$109M
3
BSX icon
Boston Scientific
BSX
+$71.4M
4
PBLS
Parabilis Medicines Inc
PBLS
+$52M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$36.3M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$141M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$80.4M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$79.8M
5
EHAB
Enhabit
EHAB
+$66.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.76%
2 Miscellaneous 16.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$2.13B 22.22%
17,248,450
– –
RVMD icon
2
Revolution Medicines
RVMD
$45.2B
$448M 4.67%
2,392,000
+95,000
+4% +$13.9M
PRAX icon
3
Praxis Precision Medicines
PRAX
$9.92B
$323M 3.36%
963,351
– –
VTRS icon
4
Viatris
VTRS
$19.5B
$321M 3.35%
20,206,170
– –
CNC icon
5
Centene
CNC
$33.6B
$315M 3.28%
4,901,000
-1,016,091
-17% -$54.3M
UTHR icon
6
United Therapeutics
UTHR
$21B
$248M 2.58%
457,000
– –
LEGN icon
7
Legend Biotech
LEGN
$4.23B
$235M 2.45%
8,137,638
+450,000
+6% +$12.1M
COGT icon
8
Cogent Biosciences
COGT
$6.06B
$194M 2.02%
5,006,104
-4,037,799
-45% -$141M
GMAB icon
9
Genmab
GMAB
$21.1B
$189M 1.97%
6,865,000
+4,403,000
+179% +$117M
BKD icon
10
Brookdale Senior Living
BKD
$2.85B
$187M 1.95%
11,637,032
– –
VERA icon
11
Vera Therapeutics
VERA
$2.52B
$168M 1.75%
3,916,400
+194,300
+5% +$7.24M
IONS icon
12
Ionis Pharmaceuticals
IONS
$9.66B
$157M 1.64%
1,979,669
– –
CELC icon
13
Celcuity
CELC
$4.72B
$152M 1.58%
1,451,014
-262,986
-15% -$30.3M
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.58B
$151M 1.57%
15,096,403
+58,403
+0.4% +$528K
NAMS icon
15
NewAmsterdam Pharma
NAMS
$3.09B
$145M 1.51%
4,264,789
– –
ACHC icon
16
Acadia Healthcare
ACHC
$2.64B
$133M 1.39%
4,520,000
– –
TNGX icon
17
Tango Therapeutics
TNGX
$3.84B
$131M 1.37%
4,190,611
+43,798
+1% +$1.08M
AHCO icon
18
AdaptHealth
AHCO
$856M
$120M 1.25%
11,477,730
– –
PHVS icon
19
Pharvaris
PHVS
$2.5B
$117M 1.22%
3,376,042
+250,000
+8% +$7.56M
ARWR icon
20
Arrowhead Research
ARWR
$12.2B
$113M 1.18%
1,389,055
-184,242
-12% -$13.6M
DNTH icon
21
Dianthus Therapeutics
DNTH
$6.03B
$110M 1.14%
1,125,313
+105,500
+10% +$9.21M
LRMR icon
22
Larimar Therapeutics
LRMR
$398M
$109M 1.13%
35,606,974
– –
MLYS icon
23
Mineralys Therapeutics
MLYS
$2.5B
$107M 1.11%
+3,958,000
New +$109M
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.86B
$101M 1.06%
2,714,503
+1,184,495
+77% +$36.3M
XENE icon
25
Xenon Pharmaceuticals
XENE
$5.85B
$97.5M 1.02%
1,615,696
– –
1
2 3 4

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q2 2026 Portfolio in Review

As of Q2 2026, Deerfield Management held 94 positions worth $9.59B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.

  • Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
  • Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
  • Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
  • Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
  • Deerfield Management's ten largest holdings make up 53% of its $9.59B portfolio in Q2 2026.
  • Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
  • Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.59B.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.